Daiichi plans its second big round of US job cuts this year
Big job cuts by drug makers have not made much news lately, given the bloodletting of the past few years that shrunk the pharmaceutical industry considerably. But Daiichi Sankyo is issuing a reminder how tenuous fortunes can be in this volatile sector.
The Japanese drug maker plans to eliminate anywhere from 1,000 to 1,200 jobs in its US commercial operations over the next several months. The cuts include an unspecified number of sales reps across the country as well as other positions in its US headquarters in Parsippany, NJ. The cuts are not expected to involve R&D operations based nearby.